Sandoz
Novartis to unify Fougera’s US manufacturing plants
March 11, 2016Manufacturing and Production, Medical Communications Fougera, Novartis, Sandoz, manufacturing
Novartis is planning to unify the two manufacturing plants used by Sandoz unit Fougera Pharmaceuticals in the US, expanding and …
Amgen sues Novartis over Enbrel biosimilar
March 3, 2016Research and Development, Sales and Marketing Amgen, Novartis, Sandoz, biosimilars
Amgen has filed a suit in a US court against Novartis’ generics unit Sandoz, in a bid to protect bestselling …
Biosimilars: Can the US catch up in 2016?
February 12, 2016Medical Communications, Sales and Marketing Eli Lilly, Enbrel, FDA, Neulasta, Novartis, Pfizer, Sandoz, Zarxio, biosimilars
What are biosimilars? Biosimilars are essentially the biological equivalent of generic drugs to their branded small-molecule counterparts (what Ibuprofen is …
Sandoz buys rights to Pfizer biosimilar
February 12, 2016Medical Communications, Research and Development, Sales and Marketing Pfiizer, Sandoz, biosimilars
Sandoz has announced further expansion to its biosimilars programme with the acquisition of the European rights to Pfizer’s Remicade (infliximab) …
EMA accepts Sandoz Neulasta biosimilar for review
February 11, 2016Research and Development Amgen, Neulasta, Novartis, Sandoz
Sandoz says the European Medicines Agency (EMA) has accepted the marketing authorization application (MAA) for its proposed biosimilar to Amgen’s …
Sandoz announces biosimilar successes
December 8, 2015Manufacturing and Production American Society of Hematology, Enbrel, Neulasta, Sandoz, ash, biosimilars, etanercept, pegfilgrastim
Novartis’ biosimilars division Sandoz has announced progress in its biosimilars programme, with its version of Amgen’s Neulasta proving as effective …
FDA accepts regulatory submission for Novartis biosimilar
November 18, 2015Research and Development, Sales and Marketing Neulasta, Novartis, Sandoz, biosimilar, pegfilgrastim
Novartis’ generics unit Sandoz has announced it has had its Biologics License Application (BLA) for a proposed biosimilar to Amgen’s …
Novartis misses Q3 forecast with $390m settlement payment, strong dollar
October 27, 2015Manufacturing and Production, Sales and Marketing Alcon, Novartis, Sandoz
Novartis reported lower-than anticipated third quarter earnings on Tuesday, hit by the $390 million settlement it has agreed to pay …
FDA accepts Sandoz submission for Amgen biosimilar
October 2, 2015Medical Communications, Research and Development Amgen, FDA, Novartis, Sandoz, biosimilars
Sandoz, a Novartis company and a global leader in biosimilars, has announced today that the US Food and Drug Administration …
Sandoz opens €150m manufacturing facility
September 18, 2015Manufacturing and Production Austria, BioInject, Novartis, Sandoz
Sandoz has opened a €150m state-of-the-art biopharmaceutical manufacturing facility in Schaftenau, Austria. Known as BioInject will result in the creation …
Sandoz launches first US biosimilar
September 3, 2015Manufacturing and Production, Sales and Marketing Amgen, Neupogen, Novartis, Sandoz, Zarxio, biosimilar, biosimilars, filgrastim
Sandoz, the generics arm of the pharma giants Novartis, has become the first company to launch a biosimilar product in …
Takeda in Velcade patent blow
August 25, 2015Manufacturing and Production Actavis, Sandoz, Takeda, Velcade, bortezomib, ixazomib
Takeda has lost a court case contesting the patent for its blockbuster multiple myeloma drug Velcade, in a decision that …
Sandoz and pharma division boost Novartis sales
July 21, 2015Sales and Marketing Alcon, Novartis, Sandoz, financial performance, financial results, income, profits, sales
Sales at Novartis reached $12.7 billion in the second quarter of 2015, while its operating income was $2.3 billion, the …
Novartis and Pfizer to close factories in India
July 21, 2015Manufacturing and Production India, Novartis, Pfizer, Sandoz, manufacturing
Two big pharma firms have announced they will close manufacturing facilities in India as they seek to restructures their global …
Novartis invests further into Poland
May 11, 2015Manufacturing and Production, Sales and Marketing Novartis, Poland, Sandoz, manufacturing, packaging
Sandoz the generics division of Novartis has opened a large packaging centre in Stryków in Poland. Valued at 171 million …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
